Compare OGEN & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | VTAK |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | 2010 | 2018 |
| Metric | OGEN | VTAK |
|---|---|---|
| Price | $0.60 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 58.3K |
| Earning Date | 05-11-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | N/A | $1,170.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.11 | $0.15 |
| 52 Week High | $9.16 | $4.31 |
| Indicator | OGEN | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 44.21 |
| Support Level | $0.56 | $0.79 |
| Resistance Level | $0.66 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 44.49 | 45.21 |
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.